1. Home
  2. SKYW vs ITRM Comparison

SKYW vs ITRM Comparison

Compare SKYW & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKYW
  • ITRM
  • Stock Information
  • Founded
  • SKYW 1972
  • ITRM 2015
  • Country
  • SKYW United States
  • ITRM Ireland
  • Employees
  • SKYW N/A
  • ITRM N/A
  • Industry
  • SKYW Air Freight/Delivery Services
  • ITRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • SKYW Consumer Discretionary
  • ITRM Health Care
  • Exchange
  • SKYW Nasdaq
  • ITRM Nasdaq
  • Market Cap
  • SKYW N/A
  • ITRM 35.6M
  • IPO Year
  • SKYW N/A
  • ITRM 2018
  • Fundamental
  • Price
  • SKYW $88.52
  • ITRM $1.06
  • Analyst Decision
  • SKYW Strong Buy
  • ITRM Strong Buy
  • Analyst Count
  • SKYW 3
  • ITRM 1
  • Target Price
  • SKYW $120.67
  • ITRM $5.00
  • AVG Volume (30 Days)
  • SKYW 453.5K
  • ITRM 424.9K
  • Earning Date
  • SKYW 04-24-2025
  • ITRM 05-12-2025
  • Dividend Yield
  • SKYW N/A
  • ITRM N/A
  • EPS Growth
  • SKYW 219.12
  • ITRM N/A
  • EPS
  • SKYW 8.74
  • ITRM N/A
  • Revenue
  • SKYW $3,672,761,000.00
  • ITRM N/A
  • Revenue This Year
  • SKYW $10.89
  • ITRM N/A
  • Revenue Next Year
  • SKYW $4.14
  • ITRM $150.10
  • P/E Ratio
  • SKYW $10.15
  • ITRM N/A
  • Revenue Growth
  • SKYW 20.53
  • ITRM N/A
  • 52 Week Low
  • SKYW $64.61
  • ITRM $0.81
  • 52 Week High
  • SKYW $135.57
  • ITRM $3.02
  • Technical
  • Relative Strength Index (RSI)
  • SKYW 51.54
  • ITRM 40.47
  • Support Level
  • SKYW $85.17
  • ITRM $1.21
  • Resistance Level
  • SKYW $90.49
  • ITRM $1.34
  • Average True Range (ATR)
  • SKYW 4.14
  • ITRM 0.09
  • MACD
  • SKYW 0.81
  • ITRM 0.02
  • Stochastic Oscillator
  • SKYW 69.41
  • ITRM 12.20

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: